<DOC>
	<DOCNO>NCT00251641</DOCNO>
	<brief_summary>This Phase 3b , randomize , parallel-group , multicenter , active-controlled , open-label study efficacy safety infliximab compare methotrexate ( MTX ) treatment moderate severe psoriasis adult diagnose moderate severe plaque-type psoriasis least 6 month prior screen ( subject concurrent psoriatic arthritis may also enrol ) .</brief_summary>
	<brief_title>The Effects Infliximab Versus Methotrexate Treatment Moderate Severe Psoriasis ( Study P04271AM2 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Adult male female subject ( &gt; = 18 75 year age ) diagnosis moderate severe plaquetype psoriasis least 6 month prior study screen ( subject concurrent psoriatic arthritis may also enrol ) . Subjects must eligible phototherapy systemic therapy psoriasis must Baseline Psoriasis Area Severity Index ( PASI ) score 12 great least 10 % total body surface area ( BSA ) involve Baseline . Subjects must agree avoid prolonged sun exposure avoid use tan booths ultraviolet light source study . Subjects must also meet tuberculosis ( TB ) eligibility assessment screen criterion follow : Have history latent active TB prior screen ; sign symptom suggestive active TB upon medical history and/or physical examination ; recent close contact person active TB , contact , refer physician specialize TB undergo additional evaluation , warrant , receive appropriate treatment latent TB prior simultaneously first administration study medication ; within 1 month prior first administration study medication , either negative diagnostic TB test result ( defined 2 negative tuberculin skin test ) OR newly identify positive diagnostic TB test result ( define least 1 positive tuberculin skin test ) screen active TB rule appropriate treatment latent TB initiate either prior simultaneously first administration study medication . Subjects must chest xray ( posterioranterior lateral ) within 3 month prior Screening evidence malignancy , infection , fibrosis , current old active TB . Specific parameter must also meet regard screen laboratory test result liver enzymes order eligible participate study . Subjects nonplaque form psoriasis , current druginduced psoriasis , pregnant , nursing , plan pregnancy ; Subjects previously treat MTX infliximab ; subject take specific drug within specified time frame prior Baseline follow : therapeutic agent target reduce tumor necrosis factor ( TNF ) biologic , live virus bacterial vaccination within 3 month ; systemic medication treatment could affect psoriasis PASI evaluation , systemic immunosuppressant lithium within 4 week ; topical medication treatment could affect psoriasis PASI evaluation within 2 week . The allowed topical treatment psoriasis shampoo ( contain tar salicylic acid ) topical moisturizers . Subjects use topical agent morning prior study visit . Nonmedicated shampoo may use morning visit . Subjects poor health , include concomitant congestive heart failure ( CHF ) ; history chronic recurrent infectious disease , specify ; human immunodeficiency virus , hepatitis B , hepatitis C ; demyelinate disease symptom suggestive multiple sclerosis optic neuritis ; systemic lupus erythematosus ; serious infection ( eg , hepatitis , pneumonia , pyelonephritis ] , hospitalize receive IV antibiotic , opportunistic infection ( eg , cytomegalovirus , Pneumocystis carinii , aspergillosis , histoplasmosis , mycobacteria TB ) , transplant organ within specified time frame ; condition specify protocol . Subjects use investigational drug within 4 week Screening , participate clinical study , staff family member study staff exclude participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>